 Proto-Oncogene Proteins p21(ras)
"Proto-Oncogene Proteins p21(ras)" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cellular proteins encoded by the H-ras, K-ras and N-ras genes. The proteins have GTPase activity and are involved in signal transduction as monomeric GTP-binding proteins. Elevated levels of p21 c-ras have been associated with neoplasia. This enzyme was formerly listed as EC 3.6.1.47.
| Descriptor ID |
D016283
|
| MeSH Number(s) |
D08.811.277.040.330.300.400.500.600 D12.644.360.525.500.600 D12.776.157.325.515.500.600 D12.776.476.525.500.600 D12.776.624.664.700.200
|
| Concept/Terms |
Proto-Oncogene Proteins p21(ras)- Proto-Oncogene Proteins p21(ras)
- p21 c-ras
- c-ras, p21
- p21 c ras
- p21(c-ras)
- ras Proto-Oncogene Protein p21
- ras Proto Oncogene Protein p21
- Proto-Oncogene Proteins c-ras
- Proteins c-ras, Proto-Oncogene
- Proto Oncogene Proteins c ras
- c-ras, Proto-Oncogene Proteins
- Proto-Oncogene Protein ras
- Proto Oncogene Protein ras
- ras, Proto-Oncogene Protein
- ras Proto-Oncogene Product p21
- ras Proto Oncogene Product p21
- c-ras Proteins
- c ras Proteins
- p21(ras)
- Proto-Oncogene Protein p21(ras)
Proto-Oncogene Protein p21(c-Ha-ras)- Proto-Oncogene Protein p21(c-Ha-ras)
- p21 c-Ha-ras
- c-Ha-ras, p21
- p21 c Ha ras
- p21(c-Ha-ras)
- p21 c-H-ras
- c-H-ras, p21
- p21 c H ras
- c-Ha-ras p21
- c Ha ras p21
- p21, c-Ha-ras
Proto-Oncogene Protein p21(c-Ki-ras)- Proto-Oncogene Protein p21(c-Ki-ras)
- p21 c-Ki-ras
- c-Ki-ras, p21
- p21 c Ki ras
- p21(c-Ki-ras)
- p21 c-K-ras
- c-K-ras, p21
- p21 c K ras
- c-Ki-ras p21
- c Ki ras p21
- p21, c-Ki-ras
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins p21(ras)".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins p21(ras)".
This graph shows the total number of publications written about "Proto-Oncogene Proteins p21(ras)" by people in this website by year, and whether "Proto-Oncogene Proteins p21(ras)" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 | | 1996 | 3 | 4 | 7 | | 1997 | 5 | 3 | 8 | | 1998 | 1 | 2 | 3 | | 1999 | 2 | 1 | 3 | | 2000 | 1 | 0 | 1 | | 2001 | 3 | 0 | 3 | | 2002 | 0 | 2 | 2 | | 2003 | 0 | 2 | 2 | | 2004 | 1 | 1 | 2 | | 2006 | 2 | 2 | 4 | | 2007 | 0 | 1 | 1 | | 2008 | 2 | 4 | 6 | | 2009 | 0 | 6 | 6 | | 2010 | 0 | 3 | 3 | | 2011 | 0 | 4 | 4 | | 2012 | 1 | 6 | 7 | | 2013 | 2 | 8 | 10 | | 2014 | 0 | 7 | 7 | | 2015 | 3 | 5 | 8 | | 2016 | 1 | 4 | 5 | | 2017 | 8 | 2 | 10 | | 2018 | 0 | 6 | 6 | | 2019 | 6 | 3 | 9 | | 2020 | 4 | 3 | 7 | | 2021 | 5 | 3 | 8 | | 2022 | 2 | 3 | 5 | | 2023 | 1 | 3 | 4 | | 2024 | 5 | 2 | 7 | | 2025 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins p21(ras)" by people in Profiles.
-
Li C, Syed MU, Nimbalkar A, Shen Y, Vieira MD, Fraser C, Inde Z, Qin X, Ouyang J, Kreuzer J, Clark SE, Kelley G, Hensley EM, Morris R, Lazaro R, Belmonte B, Oh A, Walcott M, Nabel CS, Caenepeel S, Saiki AY, Rex K, Lipford JR, Heist RS, Lin JJ, Haas W, Sarosiek K, Hughes PE, Hata AN. LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers. Nat Commun. 2025 May 02; 16(1):4112.
-
von Itzstein MS, Burns TF, Dowell JE, Horn L, Camidge DR, York SJ, Eaton KD, Kyle K, Fattah F, Liu J, Mu-Mosley H, Gupta A, Nadeem U, Gao A, Zhang S, Gerber DE. Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2025 Feb 17; 31(4):639-648.
-
Song X, Zhou Z, Elmezayen A, Wu R, Yu C, Gao B, Minna JD, Westover KD, Zeh HJ, Kroemer G, Heasley LE, Kang R, Tang D. SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition. Sci Adv. 2024 Dec 13; 10(50):eadq4274.
-
Freeland J, Mu?oz M, O'Donnell E, Langerman J, Darrow M, Bergonio J, Suarez-Navarro J, Thorpe S, Canter R, Randall RL, Plath K, Carraway KL, Witte ON, Graeber TG, Carr-Ascher JR. Genetic Screen in a Preclinical Model of Sarcoma Development Defines Drivers and Therapeutic Vulnerabilities. Clin Cancer Res. 2024 Nov 01; 30(21):4957-4973.
-
Anastasiou P, Moore C, Rana S, Tomaschko M, Pillsbury CE, de Castro A, Boumelha J, Mugarza E, de Carn? Tr?cesson S, Mikolajczak A, Blaj C, Goldstone R, Smith JAM, Quintana E, Molina-Arcas M, Downward J. Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade. Nat Commun. 2024 Sep 25; 15(1):8146.
-
Watson AS, Krause HB, Elliott A, Farrell A, Liu SV, Ma PC, VanderWalde A, Sledge GW, Spetzler D, Schenk EL, Camidge DR. Use of Oncogene Overlap by Tissue-Based Next-Generation Sequencing to Explore the Mutational Landscape and Survival Impact of HER2, KRAS and MET Copy-Number Gain in Nonsmall Cell Lung Cancer. Clin Lung Cancer. 2024 Dec; 25(8):712-722.e1.
-
Sigafoos AN, Tolosa EJ, Carr RM, Fernandez-Barrena MG, Almada LL, Pease DR, Hogenson TL, Raja Arul GL, Mousavi F, Sen S, Vera RE, Marks DL, Flores LF, LaRue-Nolan KC, Wu C, Bamlet WR, Vrabel AM, Sicotte H, Schenk EL, Smyrk TC, Zhang L, Rabe KG, Oberg AL, Zaphiropoulos PG, Chevet E, Graham RP, Hagen CE, di Magliano MP, Elsawa SF, Pin CL, Mao J, McWilliams RR, Fernandez-Zapico ME. KRAS Promotes GLI2-Dependent Transcription during Pancreatic Carcinogenesis. Cancer Res Commun. 2024 07 01; 4(7):1677-1689.
-
Singh A, Gorell ES, Lucky AW. Topical everolimus therapy for epidermal nevi associated with woolly hair nevus in a patient with a mosaic HRAS mutation. Pediatr Dermatol. 2024 Sep-Oct; 41(5):871-873.
-
Pant S, Wainberg ZA, Weekes CD, Furqan M, Kasi PM, Devoe CE, Leal AD, Chung V, Basturk O, VanWyk H, Tavares AM, Seenappa LM, Perry JR, Kheoh T, McNeil LK, Welkowsky E, DeMuth PC, Haqq CM, O'Reilly EM. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat Med. 2024 Feb; 30(2):531-542.
-
Masugi Y, Takamatsu M, Tanaka M, Hara K, Inoue Y, Hamada T, Suzuki T, Arita J, Hirose Y, Kawaguchi Y, Nakai Y, Oba A, Sasahira N, Shimane G, Takeda T, Tateishi K, Uemura S, Fujishiro M, Hasegawa K, Kitago M, Takahashi Y, Ushiku T, Takeuchi K, Sakamoto M. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression. J Pathol Clin Res. 2023 09; 9(5):339-353.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|